NanoViricides Announces That The Company Has Been Invited To Present at Dengue Research Meeting Sponsored by the National Institutes of Health
WEST HAVEN, Conn.--(BUSINESS WIRE)--Dec 21, 2010 - NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") has been invited to present at the meeting “A Re-Emerging Challenge in the Americas: Opportunities for Dengue Research Collaborations” sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) to be held February 15-18, 2011 in San Juan, Puerto Rico. The Company will present the results of its anti-Dengue drug candidates. Information about this conference can be obtained at https://conferences.niaid.nih.gov/DengueAbstracts/Pages/default.aspx.
The objective of this prestigious meeting is to provide a forum to promote and stimulate new or enhanced research collaborations in the Americas for the development of diagnostics, therapeutics and vaccines. The Company has previously reported that its anti-Dengue nanoviricide® drug candidates demonstrated significant protection in animal survival studies of Dengue virus infection in a collaboration with the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley (UC Berkeley). Dr. Harris, as well as Dr. Harold Margolis, Chief of the Dengue Branch of the CDC, will also be attending the meeting.
Dengue is endemic in Mexico, the Caribbean, Central America, as well as many countries in South America, and is a rising infection in all tropical countries. Dengue infections have occurred in the southern US states, and travel leads to sporadic cases of dengue in the USA. According to WHO, dengue threatens over 40% of the world population.
Currently, there are no approved anti-dengue drugs or vaccines.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
Contact: NanoViricides, Inc.
Amanda Schuon, 310-550-7200
Posted: December 2010